<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05109819</url>
  </required_header>
  <id_info>
    <org_study_id>AA 2112 ESO-SPARE</org_study_id>
    <secondary_id>H-20069184</secondary_id>
    <nct_id>NCT05109819</nct_id>
  </id_info>
  <brief_title>ESO-SPARE: Esophagus Sparring Radiotherapy for Thoracic and Cervical Metastatic Spinal Cord Compression.</brief_title>
  <acronym>ESO-SPARE</acronym>
  <official_title>ESO-SPARE: Esophagus Sparring Radiotherapy for Thoracic and Cervical Metastatic Spinal Cord Compression. A Randomized Phase III Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Danish Cancer Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metastatic spinal cord compression (MSCC) is a serious complication to metastatic cancer and&#xD;
      when diagnosed life expectancy is short. Treatment is palliative radiotherapy (RT). Early&#xD;
      esophageal toxicity is underreported but can seriously impact quality of life (QoL).&#xD;
&#xD;
      The aim of the ESO-SPARE trial is to investigate if esophagus sparing RT can decrease patient&#xD;
      reported esophageal toxicity without compromising ambulatory function or increase other&#xD;
      toxicities.&#xD;
&#xD;
      200 patients with MSCC in the thoracic or cervical spine referred for RT will be randomized&#xD;
      to either standard or esophagus/pharynx sparing RT. Subsequently participants will be&#xD;
      followed with PROM (Patient Reported Outcome Measures) for 9 weeks. PROM-CTCAE questionnaires&#xD;
      on upper GI toxicity and pain will be collected daily for 5 weeks and weekly for 4 weeks.&#xD;
      Questionnaires evaluating QoL and physical function will be collected weekly for 9 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients with metastatic spinal cord compression in the cervical and/or thoracic spine are randomized into two groups. Group A receives standard radiotherapy, group B receives esophagus sparing therapy.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>The outcome of randomization is not reviled to the patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Early patient reported gastro-oesophageal toxicity</measure>
    <time_frame>Measured within the first 5 weeks after treatment start</time_frame>
    <description>Measured as a peak score using CTCAE Patient Reported Outcome Measures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ambulatory function</measure>
    <time_frame>Measured 9 weeks after treatment start</time_frame>
    <description>Preserved ability to walk will be evaluated using the European Quality of Life - 5 Dimensions questionnaire (EQ-5D-5L) mobility dimension. The EQ-5D includes one question for each of the five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of gastro-oesophageal toxicity</measure>
    <time_frame>Assessed 9 weeks after treatment start</time_frame>
    <description>Measured as the time from an increase in gastro-oesophageal symptom score to a return to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reirradiation rate - Overall survival (OS)</measure>
    <time_frame>Assessed 6 months after inclusion of the last patient.</time_frame>
    <description>Defined as fraction of patients getting reirradiation, where the same spine levels are included in the irradiated volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported physical function</measure>
    <time_frame>Assessed Weekly over a period of 9 weeks</time_frame>
    <description>Patient reported physical function will be assessed using answers from the EORTC QLQ-C30 questionnaire. Questions regarding physical function are measured on a four-point scale (1= not at all, 2 = a little, 3 = quite a bit, 4 = very much). All EORTC QLQ-C30 answers will be scored according to the EORTC QLQ-C30 Scoring Manual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of life (QoL)</measure>
    <time_frame>Assessed Weekly over a period of 9 weeks</time_frame>
    <description>Health related quality of life measured with EQ-5D-5L European Quality of Life - 5 Dimensions questionnaire (EQ-5D-5L).&#xD;
The EQ-5D includes one question for each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has five response levels: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). Health state scores are defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health).&#xD;
A visual analogue scale indicating the respondent's own assessment of their health status from 0-100 is also included (100 = the best health you can imagine and 0 = the worst health you can imagine).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related Quality of life (QoL)</measure>
    <time_frame>Assessed Weekly over a period of 9 weeks</time_frame>
    <description>Health related quality of life assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire - Cancer (QLQ-C30). The EORTC QLQ-C30 consists of 30 questions assessing quality of life issues using a four-point scale (1= not at all, 2 = a little, 3 = quite a bit, 4 = very much) except from the last two questions which are measured between 1 (Very Poor) to 7 (Excellent). The EORTC QLQ-C30 will be scored according to the EORTC QLQ-C30 Scoring Manual.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Assessed Weekly over a period of 9 weeks</time_frame>
    <description>Assessed Weekly over a period of 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic consumption</measure>
    <time_frame>Assessed Weekly over a period of 9 weeks</time_frame>
    <description>Assessed Weekly over a period of 9 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain (MSCC site)</measure>
    <time_frame>Assessed daily for 5 weeks and subsequently weekly for 4 weeks.</time_frame>
    <description>Evaluated by &quot;Numeric Pain Rating Scale (NPRS)&quot;&#xD;
The scale is composed of 0 (no pain at all) to 10 (worst imaginable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain assessment (MTS site)</measure>
    <time_frame>Best response during 9 weeks of follow-up</time_frame>
    <description>Assessment will be performed using International Consensus Pain Response Endpoints (ICPRE).&#xD;
A complete pain response is defined as a pain score of 0 out of 10 at the treated site with no concomitant increase in analgesic intake&#xD;
A partial pain response is defined as a pain reduction of 2 or more at the treated site without analgesic increase, or an analgesic reduction of 25% with no increase in pain score or 1 point above baseline.&#xD;
Pain progression is defined as an increase in pain score of 2 or more above baseline with stable analgesic intake or an analgesic increase of 25% with stable pain score.&#xD;
An indeterminate response is any response not captured in the above definitions.&#xD;
Analysis of pain reduction will only include patients with NPRS ≥ 1 registered at baseline. We intend to report the best response during follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Metastatic Spinal Cord Compression</condition>
  <condition>Radiation Toxicity</condition>
  <condition>Esophagitis</condition>
  <condition>Patient Reported Outcome Measures</condition>
  <arm_group>
    <arm_group_label>Arm A: standard radiotherapy treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in arm A will receive standard radiotherapy treatment for metastatic spinal cord compression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: esophagus sparring radiotherapy treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in arm B will receive esophagus sparring radiotherapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Esophagus sparring radiotherapy treatment</intervention_name>
    <description>A radiotherapy plan for metastatic spinal cord compression is conducted with specific constrains sparring the esophagus.</description>
    <arm_group_label>Arm B: esophagus sparring radiotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histology or cytology proven cancer&#xD;
&#xD;
          -  Referred for palliative radiotherapy of the cervical or thoracic vertebra for&#xD;
&#xD;
               -  epidural ingrowth&#xD;
&#xD;
               -  metastatic spinal cord compression&#xD;
&#xD;
               -  metastatic spinal nerve root compression&#xD;
&#xD;
               -  post-operative radiotherapy after decompressive surgery for spinal cord or nerve&#xD;
                  root compression&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          -  Referred for the following dose prescriptions 5 Gy x 5, 5 Gy x 4, 3 Gy x 10, 10 Gy x&#xD;
             1, 8 Gy x 1.&#xD;
&#xD;
          -  ≥ 18 years old.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Referred for &gt; 10 fractions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna M Nielsen, MD</last_name>
    <phone>00 45 26718136</phone>
    <email>anna.mann.nielsen@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gitte Persson, MD, Ph.d.</last_name>
    <phone>00 45 38689299</phone>
    <email>Gitte.Persson@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten H Suppli, MD, PhD.</last_name>
      <phone>00 45 35459698</phone>
      <email>morten.hiul.suppli@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Ivan R Vogelius, Dr. med, clinical proffesor</last_name>
      <phone>00 45 35459885</phone>
      <email>ivan.richter.vogelius@regionh.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Herlev Hospatal</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna M Nielsen</last_name>
      <phone>+4526718136</phone>
      <email>anna.mann.nielsen@regionh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Gitte Persson</last_name>
      <phone>+4538689299</phone>
      <email>Gitte.Persson@regionh.dk</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </reference>
  <reference>
    <citation>Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001 Jul;33(5):337-43. Review.</citation>
    <PMID>11491192</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 7, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Anna Mann Nielsen</investigator_full_name>
    <investigator_title>Principal Investigator, MD</investigator_title>
  </responsible_party>
  <keyword>Metastatic Spinal Cord Compression</keyword>
  <keyword>Radiation Toxicity</keyword>
  <keyword>Esophagitis</keyword>
  <keyword>Patient reported outcome measures</keyword>
  <keyword>Palliative radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
    <mesh_term>Spinal Cord Compression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

